[1]
|
Teare, D. (1958) Asymmetrical Hypertrophy of the Heart in Young Adults. British Heart Journal, 20, 1-8.
https://doi.org/10.1136/hrt.20.1.1
|
[2]
|
Maron, B., Rowin, E., Casey, S., et al. (2015) Hypertrophic Cardiomyopa-thy in Adulthood Associated with Low Cardiovascular Mortality with Contemporary Management Strategies. Journal of the American College of Cardiology, 65, 1915-1928. https://doi.org/10.1016/j.jacc.2015.02.061
|
[3]
|
Spudich, J. (2019) Three Perspectives on the Molecular Basis of Hypercontractility Caused by Hypertrophic Cardiomyopathy Muta-tions. Pflugers Archiv: European Journal of Physiology, 471, 701-717.
https://doi.org/10.1007/s00424-019-02259-2
|
[4]
|
Jacobson, J. (2019) Arrhythmia Evaluation and Management. Cardiology Clinics, 37, 55-62.
https://doi.org/10.1016/j.ccl.2018.08.005
|
[5]
|
Maron, B. (2018) Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 379, 655-668. https://doi.org/10.1056/NEJMra1710575
|
[6]
|
邹玉宝, 宋雷. 中国成人肥厚型心肌病诊断与治疗指南解读[J]. 中国循环杂志, 2018, 33(S2): 68-73.
|
[7]
|
戴霞飞, 李小平. 肥厚型心肌病的遗传学进展[J]. 医学综述, 2018, 24(20): 3953-3958.
|
[8]
|
Elliott, P. and Mckenna, W. (2004) Hypertrophic Cardiomyopathy. The Lancet (London, Eng-land), 363, 1881-1891.
https://doi.org/10.1016/S0140-6736(04)16358-7
|
[9]
|
Williams, L. and Frenneaux, M. (2007) Syncope in Hyper-trophic Cardiomyopathy: Mechanisms and Consequences for Treatment. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology, 9, 817-822.
|
[10]
|
Nagueh, S., Phelan, D., Abraham, T., et al. (2022) Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardi-ology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 35, 533-569. https://doi.org/10.1016/j.echo.2022.03.012
|
[11]
|
Caselli, S., Maron, M., Urbano-Moral, J., et al. (2014) Differentiating Left Ventricular Hypertrophy in Athletes from That in Patients with Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 114, 1383-1389.
https://doi.org/10.1016/j.amjcard.2014.07.070
|
[12]
|
邵虹, 马志玲, 刘丽文. 肥厚型心肌病心电图特征分析[J]. 临床心电学杂志, 2015, 24(3): 177-180.
|
[13]
|
Mcleod, C., Ackerman, M., Nishimura, R., et al. (2009) Outcome of Pa-tients with Hypertrophic Cardiomyopathy and a Normal Electrocardiogram. Journal of the American College of Cardiol-ogy, 54, 229-233.
https://doi.org/10.1016/j.jacc.2009.02.071
|
[14]
|
Maron, B. and Maron, M. (2013) Hypertrophic Cardiomyopathy. The Lancet (London, England), 381, 242-255.
https://doi.org/10.1016/S0140-6736(12)60397-3
|
[15]
|
Luckie, M. and Khattar, R. (2008) Systolic Anterior Motion of the Mitral Valve—Beyond Hypertrophic Cardiomyopathy. Heart (British Cardiac Society), 94, 1383-1385. https://doi.org/10.1136/hrt.2007.122069
|
[16]
|
Maron, M., Olivotto, I., Betocchi, S., et al. (2003) Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. The New England Journal of Medicine, 348, 295-303.
https://doi.org/10.1056/NEJMoa021332
|
[17]
|
王怀根, 卢群, 马爱群. 《中国成人肥厚型心肌病诊断与治疗指南2023》解读[J]. 疑难病杂志, 2023, 22(6): 561-565.
|
[18]
|
徐萍萍. 实时超声心动图三维斑点追踪技术对肥厚型心肌病患者左室整体收缩功能及收缩同步性的评价应用探讨[J]. 中外医学研究, 2019, 17(21): 54-56.
|
[19]
|
彭源, 杨军, 谢明星, 等. 三维超声成像评价肥厚型心肌病左室节段收缩同步性与整体功能的初步研究[J]. 华中科技大学学报(医学版), 2016, 45(5): 523-528.
|
[20]
|
Rajtar-Salwa, R., Petkow-Dimitrow, P. and Miszalski-Jamka, T. (2016) Role of Cardiac Magnetic Resonance in Differentiating between Acute Coronary Syndrome and Apical Hypertrophic Cardiomyopathy. Advances in Interventional Cardiology, 12, 380-382. https://doi.org/10.5114/aic.2016.63642
|
[21]
|
Maron, M. and Maron, B. (2015) Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. Circulation, 132, 292-298. https://doi.org/10.1161/CIRCULATIONAHA.114.014283
|
[22]
|
Chan, R., Maron, B., Olivotto, I., et al. (2014) Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 130, 484-495. https://doi.org/10.1161/CIRCULATIONAHA.113.007094
|
[23]
|
李硕, 李成华, 靳温. 肌酸激酶-同工酶亚型的检测及其在心肌损伤中的应用[J]. 心血管康复医学杂志, 2020, 29(2): 183-186.
|
[24]
|
王付镇, 王德杰, 刘丹. 彩色多普勒心脏超声联合血清cTnI、CK-MB、NT-proBNP检测在老年肥厚型梗阻性心肌病诊断中的应用效果[J]. 影像研究与医学应用, 2022, 6(15): 13-15.
|
[25]
|
钟文津, 景香香, 唐海霞, 等. 彩色多普勒心脏超声联合血清cTnI、CK-MB、NT-proBNP检测在老年肥厚型梗阻性心肌病诊断中的应用[J]. 中国老年学杂志, 2021, 41(16): 3396-3399.
|
[26]
|
Sherrid, M. (2016) Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Current Cardiology Reviews, 12, 52-65. https://doi.org/10.2174/1573403X1201160126125403
|
[27]
|
Rowin, E., Hausvater, A., Link, M., et al. (2017) Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 136, 2420-2436. https://doi.org/10.1161/CIRCULATIONAHA.117.029267
|
[28]
|
Baker, J. (2010) The Selectivity of beta-Adrenoceptor Agonists at Human beta1-, beta2- and beta3-Adrenoceptors. British Journal of Phar-macology, 160, 1048-1061. https://doi.org/10.1111/j.1476-5381.2010.00754.x
|
[29]
|
Elliott, P., Anastasakis, A., Borger, M., et al. (2014) 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35, 2733-2779.
https://doi.org/10.1093/eurheartj/ehu284
|
[30]
|
Sherrid, M., Shetty, A., Winson, G., et al. (2013) Treatment of Ob-structive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy with β-Blockade or Ve-rapamil. Circulation Heart Failure, 6, 694-702.
https://doi.org/10.1161/CIRCHEARTFAILURE.112.000122
|
[31]
|
Smedira, N., Lytle, B., Lever, H., et al. (2008) Current Effectiveness and Risks of Isolated Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. The Annals of Thoracic Surgery, 85, 127-133.
https://doi.org/10.1016/j.athoracsur.2007.07.063
|
[32]
|
Olivotto, I., Oreziak, A., Barriales-Villa, R., et al. (2020) Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): A Ran-domised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet (London, England), 396, 759-769. https://doi.org/10.1016/S0140-6736(20)31792-X
|
[33]
|
中国成人肥厚型心肌病诊断与治疗指南2023[J]. 中国分子心脏病学杂志, 2023, 23(1): 5115-5149.
https://doi.org/10.16563/j.cnki.1671-6272.2023.02.002
|
[34]
|
Maron, B. and Nishimura, R. (2014) Surgical Septal Myectomy versus Alcohol Septal Ablation: Assessing the Status of the Controversy in 2014. Circulation, 130, 1617-1624. https://doi.org/10.1161/CIRCULATIONAHA.114.011580
|